OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 9,500 UTHR derivative securities | OQRO

Home
Insider trades
United Therapeutics
CEO exercised or converted 9,500 UTHR derivative securities

Insider trades

Insider trade

CEO exercised or converted 9,500 UTHR derivative securities

Traded Mar 11, 2026 · Filed Mar 12, 2026

UTHUnited TherapeuticsUTHR

9,500
Shares · @ $146.03

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 11, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 12, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001106578-26-000009

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Mar 12, 2026, 3:31 AM UTC

Added to OQRO

Oct 6, 2026, 9:34 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

UNITED THERAPEUTICS Corp

Issuer CIK

1082554

Ticker

UTHR

Reporting person

Martine A Rothblatt

Relationship

Director, Officer

Officer title

Chairperson & CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Mar 11, 2026

Transaction code

Shares / units

9,500

Price per share

$146.03

Acquired / disposed

Acquired (A)

Shares owned after

9,630

Ownership form

Direct

Amendment

Footnotes from the filing

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

Around the same time

James EdgemondCFO AND TREASURER

Filed 6mo ago

10KShares · @ $135.42

Traded Apr 9 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

James Edgemond (CFO AND TREASURER) sold ~$322K of United Therapeutics

Scheduled in advanceFiled 6mo ago

James Edgemond (CFO AND TREASURER) sold ~$1.13M of United Therapeutics

Scheduled in advanceFiled 6mo ago